- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04704648
Feasibility Study of Ocular Surface Squamous Neoplasia Surgical Excision in People Living With HIV in Sub-Saharan Africa
Feasibility Study of Ocular Surface Squamous Neoplasia (OSSN) Surgical Excision in People Living With HIV in Sub-Saharan Africa (SSA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The AMC-certified ophthalmologist will obtain a thorough eye history and conduct a slit-lamp examination of both eyes. The AMC-certified ophthalmologist will draw the size and shape of the suspected lesion on a well-accepted template designed for documentation of ocular surface malignancies. Using this template, the AMC-certified ophthalmologist will document the number of clock hours of corneal-scleral limbus involved (6 clock hours maximum) as well as the maximum vertical and horizontal dimensions of the lesion in mm as determined through the use of the adjustable slit beam, whose length can be adjusted and determined using the slit length display window, a standard feature of slit lamp biomicroscopes.
Eighty-four participants undergoing surgical excision of tumors suspicious for OSSN will be enrolled in this study. Participants who do not complete the study follow-up visits will not be replaced. The lesions will be swabbed prior to surgical excision and the swabs will be placed in PrimeStore MTM solution, for HPV DNA testing. The suspected OSSN lesion will be excised with 3 mm margins as determined by clinical exam. The PrimeStore MTM solution will be sent to Stellenbosch University in Cape Town, South Africa for HPV testing. The surgically excised lesions will be fixed, aligned, embedded in paraffin, sectioned and evaluated by pathologists at each of the 4 study sites. Tissue will then be sent to Stellenbosch University in Cape Town, South Africa for confirmatory histopathologic analysis and HPV testing.
To ensure reliable follow-up, we will collect detailed contact and alternate contact information from study participants. Participants will be asked to return for follow-up one week after surgery, 6 weeks after surgery, 6 months after surgery, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough medical history and perform a slit-lamp examination of the eyes. At week 2, sites will contact participants via phone to review AEs. Participants will undergo a structured review of post-surgical signs and symptoms at each follow-up visit. Participants presenting with a suspected recurrent OSSN lesion at follow-up will undergo re-excision per routine clinical care, including any follow-up per the local standard of care. After local diagnostic review, excised specimens will be sent for central histopathology evaluation and confirmation of recurrent OSSN or not recurrent OSSN. All other ocular lesions and conditions will be referred for routine medical care, outside of the study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kampala, Uganda
- Recruiting
- Uganda Cancer Institute
-
Contact:
- Anne Ampaire Musika, MMed, MSC
- Phone Number: 256772424995
- Email: annemusika@gmail.com
-
Principal Investigator:
- Anne Ampaire Musika, MMed, MSC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
3.2.1 Participants with suspected unilateral, non-invasive OSSN lesions that the AMC-certified ophthalmologist determines can be resected with 3 mm clinical margins, sparing involvement of the superior and inferior fornices as well as 6 clock hours of the corneal scleral limbus. This assessment must be carried out within 4 weeks before surgery.
3.2.2 HIV positive. Documentation of HIV-1 infection by means of any one of the following:
- Documentation of receipt of ART by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Antiretroviral drug regimens used for pre-exposure prophylaxis (PrEP) may not satisfy this requirement.;
- HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating >1000 RNA copies/mL confirmed by a licensed screening antibody and/or HIV antibody/antigen combination assay;
- Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay.
Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA).
WHO and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an enzyme or chemiluminescence assay (E/CIA) that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.
3.2.3 Performance status ≤ 2 on the WHO Scale (see Appendix III).
Exclusion Criteria:
3.3.1 Participants who are receiving any other investigational agents within 30 days before enrollment for surgery, except for investigational ART regimens, which will be permitted.
3.3.2 Participants with known history of ocular surface lesions including OSSN, other ocular neoplasm, pterygia, or limbal vernal keratoconjunctivitis.
3.3.3 Uncontrolled intercurrent illness within 4 weeks before enrollment, including but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Surgical Excision
Treatment involves EXCISION ONLY (surgery) for the conjunctival lesion with 3 mm margins.
Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP).
Standard of care topical antibiotics are given for infection prevention following surgery.
No drugs or device treatments are administered for treatment of OSSN in this protocol.
|
The treatment involves excision only of the conjunctival lesion with 3 mm margins. Surgeons (registered as investigators at each site) will perform the operation in accordance with the procedures outlined in the AMC-104 manual of procedures (MOP). As part of the study patients will be asked to return for follow-up evaluation 1 week, 6 weeks, 6 months, and 12 months after surgery. At each of these follow-up visits, the AMC-certified ophthalmologist will obtain a thorough ocular history as well as a history of AIDS-defining illnesses and perform a slit-lamp examination of both eyes, complete with templated drawings of the conjunctiva, and careful examination of the cornea for limbal stem cell deficiency. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Satisfaction of 3 feasibility criteria across all participants and satisfaction of the feasibility criteria by at least 3 of 4 of the participating centers
Time Frame: 12 months
|
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants with suspected OSSN lesions who are found to have biopsy-proven OSSN.
Time Frame: 12 months
|
Participants presenting with a suspected recurrent OSSN lesion at follow-up will undergo re-excision per routine clinical care, including any follow-up per the local standard of care.
After local diagnostic review, excised specimens will be sent for central histopathology evaluation and confirmation of recurrent OSSN or not recurrent OSSN.
|
12 months
|
To estimate the proportion of biopsy-proven OSSN lesions excised with clear margins on histopathologic analysis.
Time Frame: 12 months
|
Participants presenting with a suspected recurrent OSSN lesion at follow-up will undergo re-excision per routine clinical care, including any follow-up per the local standard of care.
After local diagnostic review, excised specimens will be sent for central histopathology evaluation and confirmation of recurrent OSSN or not recurrent OSSN.
|
12 months
|
To characterize the nature and frequency of surgical complications in participants undergoing excision of suspected OSSN.
Time Frame: 12 months
|
The chi-square test without continuity correction will be used to compare the sites. If a significant difference between sites is detected with respect to any of the feasibility endpoints. • Do not develop surgical complications. |
12 months
|
To estimate 1-year recurrence rates of biopsy-proven OSSN following surgical excision.
Time Frame: 12 months
|
We will use the HybriSpot HPV Direct Flow Chip kit (Master Diagnóstica) to detect HPV DNA in formalin-fixed paraffin-embedded (FFPE) tissue samples.
|
12 months
|
To determine whether HPV is present in biopsy-proven OSSN pathology specimens.
Time Frame: 12 months
|
We will use the HybriSpot HPV Direct Flow Chip kit (Master Diagnóstica) to detect HPV DNA in formalin-fixed paraffin-embedded (FFPE) tissue samples.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMC-104
- UM1CA121947 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingHPV Vaccine | HPVUnited States, Puerto Rico
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHPV Vaccine Attitudes | HPV Vaccine IntentionUnited States
-
Xijing HospitalEnrolling by invitationHPV Vaccination、HPV Related Diseases、Protective EfficacyChina
-
Global Alliance to Immunize Against AIDS Vaccine...Merck Sharp & Dohme LLCCompletedHPV-Related Cervical Carcinoma | HPV
-
Emory UniversityRecruiting
-
East Carolina UniversityRecruiting
-
University of FloridaNational Cancer Institute (NCI)Active, not recruiting
-
University of MinnesotaCompleted
-
Brigham and Women's HospitalNational Institutes of Health (NIH)Not yet recruiting
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian Health; The City College of New YorkActive, not recruitingHPV VaccinationUnited States
Clinical Trials on Surgical
-
AO Clinical Investigation and Publishing DocumentationAOCMFCompletedBilateral Condylar Fracture of the MandibleUnited States, Taiwan, Switzerland, South Africa, Finland, Slovenia, Pakistan, Spain, Germany, Malaysia, Mexico, Netherlands, Ukraine, Uruguay
-
Texas Scottish Rite Hospital for ChildrenRecruiting
-
HealthCore-NERIUniversity of California, San Diego; University of Maryland; University of Alabama... and other collaboratorsTerminated
-
University of BergenOslo University Hospital; Haukeland University Hospital; Skane University Hospital and other collaboratorsRecruiting
-
University of CologneCompletedOutcome, Fatal | Vertebral Osteomyelitis | Spondylodiscitis
-
Peking University Third HospitalRecruitingOsteoarthritis, Knee | Anterior Cruciate Ligament RuptureChina
-
Kolding SygehusOdense University Hospital; Karolinska University Hospital; Zealand University... and other collaboratorsRecruitingFracture Humerus of ShaftSweden, Finland, Denmark, Norway
-
The Cleveland ClinicActive, not recruitingEducational ProblemsUnited States
-
Sahlgrenska University Hospital, SwedenActive, not recruitingRupture | Ultrasonography | Acute Disease | Athletic Injuries | Achilles Tendon RuptureSweden
-
Zimmer BiometRecruitingRib; FractureAustralia, Korea, Republic of